{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:25:27Z","timestamp":1773033927091,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11926-025-01192-x","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:31:03Z","timestamp":1748421063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breaking Barriers: Essential Reforms for a Competitive and Affordable Biosimilars Market"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8435-8994","authenticated-orcid":false,"given":"Eric T.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"1192_CR1","unstructured":"IQVIA. Biosimilars in the United States 2023\u20132027: Competition, savings, and sustainability. 2023.\u00a0https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027."},{"issue":"11","key":"1192_CR2","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/acr2.11728","volume":"6","author":"Y Huang","year":"2024","unstructured":"Huang Y, Li J, Agarwal SK. Economic and Humanistic Burden of Rheumatoid Arthritis: Results From the US National Survey Data 2018\u20132020. ACR Open Rheumatol. 2024;6(11):746\u201354.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2017.12.010","volume":"48","author":"P Heidari","year":"2018","unstructured":"Heidari P, Cross W, Crawford K. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. Semin Arthritis Rheum. 2018;48(1):12\u201321.","journal-title":"Semin Arthritis Rheum"},{"key":"1192_CR4","doi-asserted-by":"crossref","unstructured":"Erath A, Dusetzina SB. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010\u20132019. JAMA Network Open. 2020;3(4):e203969-e.","DOI":"10.1001\/jamanetworkopen.2020.3969"},{"issue":"9","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.2018.7316","volume":"320","author":"J Yazdany","year":"2018","unstructured":"Yazdany J, Dudley RA, Lin GA, Chen R, Tseng C-W. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. JAMA. 2018;320(9):931\u20133.","journal-title":"JAMA"},{"issue":"6","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/art.41201","volume":"72","author":"SC Kim","year":"2020","unstructured":"Kim SC, Sarpatwari A, Landon JE, Desai RJ. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis & rheumatology. 2020;72(6):1036\u20138.","journal-title":"Arthritis & rheumatology"},{"issue":"4","key":"1192_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cpt.2322","volume":"110","author":"CC Lee","year":"2021","unstructured":"Lee CC, Najafzadeh M, Kesselheim AS, Sarpatwari A. Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clin Pharmacol Ther. 2021;110(4):1050\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1192_CR8","unstructured":"Robinson K. Most rheumatology patients have insurance but still struggle to pay for care [press release]. 2019. https:\/\/www.hcplive.com\/view\/most-rheumatology-patients-have-insurance-still-struggle-pay-care. Accessed 20 Dec 2024."},{"issue":"1","key":"1192_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","volume":"76","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Bartels D, Saedder EA, Poulsen BK, Andersen SE, Christensen MMH, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35\u201340.","journal-title":"Eur J Clin Pharmacol"},{"key":"1192_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"CA Conran","year":"2022","unstructured":"Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022;64: 102234.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"1192_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1192_CR12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1192_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"J-Y Choe","year":"2017","unstructured":"Choe J-Y, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):58\u201364.","journal-title":"Ann Rheum Dis"},{"key":"1192_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1646-4","volume":"20","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, et al. A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20:1\u201313.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1192_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49(1):31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1192_CR16","first-page":"985","volume":"29","author":"Y Yin","year":"2023","unstructured":"Yin Y, McDermott C, Lockhart C. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review. J Manag Care Spec Pharm. 2023;29(9):985\u201398.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1192_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis. PLoS ONE. 2023;18(10): e0292231.","journal-title":"PLoS ONE"},{"key":"1192_CR18","unstructured":"U.S. Food and Drug Administration. Safety Outcomes When \u201cSwitching\u201d Between Biosimilars and Reference Products 2024 [Available from: https:\/\/www.fda.gov\/drugs\/spotlight-cder-science\/safety-outcomes-when-switching-between-biosimilars-and-reference-products#footnotei_18pmtcr. Accessed 8 Aug 2024."},{"key":"1192_CR19","unstructured":"American College of Rheumatology. Presenters to review real-world evidence supporting biosimilar use [press release]. 2024.\u00a0https:\/\/www.acrconvergencetoday.org\/presenters-to-review-real-world-evidence-supporting-biosimilar-use\/. Accessed 20 Dec 2024."},{"issue":"2","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/rheumatology\/keaa502","volume":"60","author":"A Gibofsky","year":"2021","unstructured":"Gibofsky A, McCabe D. US rheumatologists\u2019 beliefs and knowledge about biosimilars: a survey. Rheumatology (Oxford). 2021;60(2):896\u2013901.","journal-title":"Rheumatology (Oxford)"},{"key":"1192_CR21","unstructured":"Curtis JR. Biosimilars in rheumatology: the forthcoming season of change in 2023. In: 2023 biosimilars report. Cardinal Health. 2023. https:\/\/www.cardinalhealth.com\/content\/dam\/corp\/web\/documents\/Report\/cardinal-health-biosimilars-report-2023.pdf. Accessed 15 Oct 2024."},{"issue":"8","key":"1192_CR22","first-page":"1129","volume":"27","author":"BS Edgar","year":"2021","unstructured":"Edgar BS, Cheifetz AS, Helfgott SM, Smith GP, Bandekar T, Hoye-Simek A, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021;27(8):1129\u201335.","journal-title":"J Manag Care Spec Pharm"},{"key":"1192_CR23","doi-asserted-by":"publisher","unstructured":"Roberts ET, Bansback N, Tseng C-W, Shiboski S, Li J, Schmajuk G, et al. Drivers of infliximab biosimilar uptake: a comparative analysis of new biosimilar initiations versus switching in a National Rheumatology Registry. Health Services Res. 2024;1\u201311. https:\/\/doi.org\/10.1111\/1475-6773.14410.","DOI":"10.1111\/1475-6773.14410"},{"issue":"1","key":"1192_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2020.3588","volume":"181","author":"CA Sacks","year":"2021","unstructured":"Sacks CA, Van de Wiele VL, Fulchino LA, Patel L, Kesselheim AS, Sarpatwari A. Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. JAMA Intern Med. 2021;181(1):16\u201322.","journal-title":"JAMA Intern Med"},{"key":"1192_CR25","unstructured":"U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: update. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update. Accessed 2 April 2025."},{"issue":"15","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jama.2024.15225","volume":"332","author":"P Cavazzoni","year":"2024","unstructured":"Cavazzoni P, Yim S. The Science of Biosimilars\u2014Updating Interchangeability. JAMA. 2024;332(15):1235\u20136.","journal-title":"JAMA"},{"key":"1192_CR27","unstructured":"Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. 2024. https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/pharmacy-benefit-managers-staff-report.pdf. Accessed 21 Aug 2024."},{"key":"1192_CR28","doi-asserted-by":"publisher","unstructured":"Roberts ET, Li J, Bansback N, Tseng CW, Shiboski S, Schmajuk G, et al. Patterns of infliximab biosimilar uptake for Medicare, Medicaid, and private insurance from 2016\u20102022. Arthritis Rheumatol. 2024;76(12):1739\u201342. https:\/\/doi.org\/10.1002\/art.42963.","DOI":"10.1002\/art.42963"},{"issue":"8","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1001\/amajethics.2019.668","volume":"21","author":"MZ Zhai","year":"2019","unstructured":"Zhai MZ, Sarpatwari A, Kesselheim AS. Why Are Biosimilars Not Living up to Their Promise in the US? AMA J Ethics. 2019;21(8):E668\u201378.","journal-title":"AMA J Ethics"},{"issue":"6","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/art.41203","volume":"72","author":"J Yazdany","year":"2020","unstructured":"Yazdany J. Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States. Arthritis & Rheumatology. 2020;72(6):870\u20133.","journal-title":"Arthritis & Rheumatology"},{"key":"1192_CR31","unstructured":"Federal Trade Commission. Pay for Delay 2025 [Available from: https:\/\/www.ftc.gov\/news-events\/topics\/competition-enforcement\/pay-delay#:~:text=Pay%2Dfor%2DDelay:%20When,%2Dfor%2Ddelay%E2%80%9D%20settlements. Accessed 31 Jan 2025."},{"issue":"2","key":"1192_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.37765\/ajmc.2023.89315","volume":"29","author":"JB Gibbons","year":"2023","unstructured":"Gibbons JB, Laber M, Bennett CL. Humira: The First $20 Billion Drug. Am J Manag Care. 2023;29(2):78\u201380.","journal-title":"Am J Manag Care"},{"key":"1192_CR33","unstructured":"PR Newswire. Express Scripts Adds Three Biosimilars to Largest Formulary to Promote Competition and Advance Affordability, Choices for Patients [press release]. 2023. https:\/\/www.prnewswire.com\/news-releases\/express-scripts-adds-three-biosimilars-to-largest-formulary-to-promote-competition-and-advance-affordability-choices-for-patients-301872877.html. Accessed 2 April 2025."},{"issue":"24","key":"1192_CR34","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/jama.2024.16911","volume":"332","author":"OJ Wouters","year":"2024","unstructured":"Wouters OJ, Vogel M, Feldman WB, Beall RF, Kesselheim AS, Tu SS. Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US. JAMA. 2024;332(24):2101\u20138.","journal-title":"JAMA"},{"key":"1192_CR35","unstructured":"SmithRx. Unraveling PBM complexity: The consequences of vertical integration. 2024. https:\/\/www.smithrx.com\/blog\/unraveling-pbm-complexity-the-consequences-of-vertical-integration. Accessed 20 Dec 2024."},{"key":"1192_CR36","unstructured":"Volansky R. CVS Caremark to replace Humira with biosimilars on national commercial formularies. Healio Rheumatol. 2024.\u00a0https:\/\/www.healio.com\/news\/rheumatology\/20240105\/cvs-caremark-to-replace-humira-with-biosimilars-on-national-commercial-formularies.\u00a0Accessed 8 Jan 2024."},{"issue":"6","key":"1192_CR37","first-page":"600","volume":"30","author":"SR Mehr","year":"2024","unstructured":"Mehr SR. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it. J Manag Care Spec Pharm. 2024;30(6):600\u20133.","journal-title":"J Manag Care Spec Pharm"},{"key":"1192_CR38","unstructured":"Roberts E, Schmajuk G, Yazdany J. Very low uptake of biosimilar adalimumab in the first 9 months of availability in rheumatology [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).https:\/\/acrabstracts.org\/abstract\/very-low-uptake-of-biosimilar-adalimumab-in-the-first-9-months-of-availability-in-rheumatology\/. Accessed\u00a020 May 2025."},{"key":"1192_CR39","unstructured":"Cohen JP. CVS caremark\u2019s policy shift on humira biosimilars may not be what the doctor ordered. Forbes. 2024. https:\/\/www.forbes.com\/sites\/joshuacohen\/2024\/05\/02\/cvs-caremarks-policy-shift-on-humira-biosimilars-may-not-be-what-the-doctor-ordered\/. Accessed 26 Mar 2025."},{"issue":"1","key":"1192_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14712598.2021.1849132","volume":"21","author":"S Simoens","year":"2021","unstructured":"Simoens S, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021;21(1):9\u201317.","journal-title":"Expert Opin Biol Ther"},{"key":"1192_CR41","doi-asserted-by":"crossref","unstructured":"San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. JAMA Network Open. 2019;2(12):e1917379-e.","DOI":"10.1001\/jamanetworkopen.2019.17379"},{"key":"1192_CR42","doi-asserted-by":"crossref","unstructured":"Rome BN, Bhaskar A, Kesselheim AS. Use, Spending, and Prices of Adalimumab Following Biosimilar Competition. JAMA Health Forum. 2024;5(12):e243964-e.","DOI":"10.1001\/jamahealthforum.2024.3964"},{"key":"1192_CR43","unstructured":"Abelson R, Robbins R. The powerful companies driving local drugstores out of business. New York Times. 2024;19. https:\/\/www.nytimes.com\/2024\/10\/19\/business\/drugstores-closing-pbm-pharmacy.html. Accessed 19 Oct 2024."},{"key":"1192_CR44","unstructured":"Hamby C. Giant companies took secret payments to allow free flow of opioids. New York Times. 2024. https:\/\/www.nytimes.com\/2024\/12\/17\/business\/pharmacy-benefit-managers-opioids.html. Accessed 17 Dec 2024."},{"key":"1192_CR45","first-page":"2024","volume":"21","author":"R Robbins","year":"2024","unstructured":"Robbins R, Abelson R. The opaque industry secretly inflating prices for prescription drugs. New York Times. 2024;21:2024.\u00a0https:\/\/www.nytimes.com\/2024\/06\/21\/business\/prescription-drug-costs-pbm.html.\u00a0Accessed\u00a021\u00a0June 2024.","journal-title":"New York Times"},{"key":"1192_CR46","unstructured":"Jeremias, S. FTC takes legal action against 3 largest pbms over insulin costs [press release]. In: The Center for Biosimilars. 2024. https:\/\/www.centerforbiosimilars.com\/view\/ftc-takes-legal-action-against-3-largest-pbms-over-insulin-costs. Accessed  31 Jan 2025."},{"key":"1192_CR47","unstructured":"Olsen, E. UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case [press release]. In:\u00a0Health Care Dive. 2024. https:\/\/www.healthcaredive.com\/news\/unitedhealth-cvs-remove-ftc-chair-lina-khan-pharmacy-benefit-manager-insulin\/729426\/#:~:text=Dive%20Brief:%20*%20UnitedHealth%20Group%20and%20CVS,and%20driving%20up%20the%20price%20of%20insulin. Accessed 31 Jan 2025."},{"key":"1192_CR48","unstructured":"US Congress, Committee on Energy & Commerce, Health Subcommittee. An examination of how reining in PBMs will drive competition and lower costs for patients: Hearing before the Energy & Commerce, United States Congress. 2025. https:\/\/energycommerce.house.gov\/events\/health-subcommittee-an-examination-of-how-reining-in-pb-ms-will-drive-competition-and-lower-costs-for-patients. Accessed 10 April 2025."},{"key":"1192_CR49","unstructured":"Preserve Access to Affordable Generics and Biosimilars Act, U.S. Senate, 119th Congress Sess. 2025. https:\/\/www.congress.gov\/bill\/119th-congress\/senate-bill\/1096. Accessed 28 April 2025."},{"key":"1192_CR50","unstructured":"Jewett C.\u00a0F.D.A. layoffs could raise drug costs and erode food safety. The New York Times. 2025;3. https:\/\/www.nytimes.com\/2025\/04\/03\/health\/fda-layoffs-food-and-drug-safety-rfk-jr.html?smid=url-share. Accessed 3 April 2025."},{"key":"1192_CR51","unstructured":"Foster E, Niyogi S, Adolph N, E Savage E. Lessons from Semglee: early perspectives on Pharmacy Biosimilars. In:\u00a0IQVIA. 2022;1. https:\/\/www.iqvia.com\/locations\/united-states\/library\/white-papers\/lessons-from-semglee-early-perspectives-on-pharmacy-biosimilars. Accessed 8 April 2025."},{"key":"1192_CR52","unstructured":"Niyogi S, Adolph N, Pashchinskiy A. Biosimilars in the U.S.: reimbursement and impacts to uptake. In:\u00a0IQVIA. 2021. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/us\/white-paper\/biosimilars-in-the-us-reimbursement-and-impacts-to-uptake.pdf. Accessed 8 April 2025."},{"key":"1192_CR53","doi-asserted-by":"crossref","unstructured":"Dickson SR, Kent T. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition. JAMA Network Open. 2021;4(11):e2133451-e.","DOI":"10.1001\/jamanetworkopen.2021.33451"},{"key":"1192_CR54","unstructured":"U.S. Department of Health & Human Services. Part B Biosimilar Biological Product Payment and Required Modifiers. 2020. Report No.: HHS-0938\u20132018-F-6824. https:\/\/www.hhs.gov\/guidance\/document\/part-b-biosimilar-biological-product-payment-and-required-modifiers. Accessed 15 Mar 2024."},{"key":"1192_CR55","unstructured":"The Rheumatologist. After coalition meeting, CMS leadership agrees to closer look at underwater biosimilars [press release]. Am College Rheumatol. 2024. https:\/\/www.the-rheumatologist.org\/article\/after-meeting-with-acr-led-coalition-cms-leadership-agrees-to-closer-look-at-underwater-biosimilars\/. Accessed 21 Oct 2024."},{"key":"1192_CR56","unstructured":"US Congress, Ways & Means Committee, Health Subcommittee. Health subcommittee hearing on lowering costs for patients: the health of the biosimilar market: hearing before the ways & means, United States Congress. 2025. https:\/\/waysandmeans.house.gov\/event\/health-subcommittee-hearing-on-lowering-costs-for-patients-the-health-of-the-biosimilar-market\/. Accessed 10 April 2025."},{"issue":"5","key":"1192_CR57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1377\/hlthaff.2022.00812","volume":"42","author":"AM Bond","year":"2023","unstructured":"Bond AM, Dean EB, Desai SM. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program. Health Aff. 2023;42(5):632\u201341.","journal-title":"Health Aff"},{"issue":"4","key":"1192_CR58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMsa2306609","volume":"390","author":"JC Robinson","year":"2024","unstructured":"Robinson JC, Whaley C, Dhruva SS. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance. N Engl J Med. 2024;390(4):338\u201345.","journal-title":"N Engl J Med"},{"issue":"11","key":"1192_CR59","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1377\/hlthaff.2024.00366","volume":"43","author":"J Jhang","year":"2024","unstructured":"Jhang J, Brennan TA. Evidence That Regulatory And Market Forces Are Driving Adoption Of Biosimilars. Health Aff (Millwood). 2024;43(11):1553\u201360.","journal-title":"Health Aff (Millwood)"},{"key":"1192_CR60","unstructured":"Mehr S. Sandoz: Patients Get a $200 Debit Card to Switch to Hyrimoz. Biosimilars Revi Rep. 2025;20. https:\/\/biosimilarsrr.com\/2025\/03\/20\/sandoz-patients-get-a-200-debit-card-to-switch-to-hyrimoz\/. Accessed 28 Mar 2025."},{"issue":"8","key":"1192_CR61","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/art.42520","volume":"75","author":"BN Rome","year":"2023","unstructured":"Rome BN, Kesselheim AS. Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups. Arthritis Rheumatol. 2023;75(8):1325\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1192_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.2024.8917","volume":"332","author":"MJ Klebanoff","year":"2024","unstructured":"Klebanoff MJ, Li P, Lin JK, Doshi JA. Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans. JAMA. 2024;332(1):74\u20136.","journal-title":"JAMA"},{"issue":"6","key":"1192_CR63","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40290-024-00541-y","volume":"38","author":"E Car","year":"2024","unstructured":"Car E, Vandenplas Y, Lacosta TB, Simoens S, Huys I, Vulto AG, et al. Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review. Pharma Med. 2024;38(6):429\u201355.","journal-title":"Pharma Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01192-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:04:03Z","timestamp":1770750243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01192-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01192-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"15 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Roberts reports no conflicts of interest. Dr Yazdany discloses consulting fees from Astra Zeneca and UCB unrelated to this work, and grant funding from Astra Zeneca, Gilead, and Aurinia, also unrelated to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"25"}}